Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
LeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsShares OutstandingShares OutstandingShares Repurchased
Ratios

Actinium Pharmaceuticals (ATNM) Accumulated Depreciation & Amortization (2021 - 2023)

Actinium Pharmaceuticals (ATNM) has disclosed Accumulated Depreciation & Amortization for 5 consecutive years, with -$112000.0 as the latest value for Q4 2023.

  • Quarterly Accumulated Depreciation & Amortization fell 165.12% to -$112000.0 in Q4 2023 from the year-ago period, while the trailing twelve-month figure was -$112000.0 through Dec 2023, down 165.12% year-over-year, with the annual reading at -$112000.0 for FY2023, 165.12% down from the prior year.
  • Accumulated Depreciation & Amortization for Q4 2023 was -$112000.0 at Actinium Pharmaceuticals, down from $172000.0 in the prior quarter.
  • The five-year high for Accumulated Depreciation & Amortization was $172000.0 in Q4 2022, with the low at -$112000.0 in Q4 2023.
  • Average Accumulated Depreciation & Amortization over 3 years is $65333.3, with a median of $136000.0 recorded in 2021.
  • The sharpest move saw Accumulated Depreciation & Amortization rose 26.47% in 2022, then tumbled 165.12% in 2023.
  • Over 3 years, Accumulated Depreciation & Amortization stood at $136000.0 in 2021, then grew by 26.47% to $172000.0 in 2022, then plummeted by 165.12% to -$112000.0 in 2023.
  • According to Business Quant data, Accumulated Depreciation & Amortization over the past three periods came in at -$112000.0, $172000.0, and $136000.0 for Q4 2023, Q4 2022, and Q4 2021 respectively.